HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wahl, R. L. Articles by Zasadny, K. R. Search for Related Content PubMed PubMed Citation Articles by Wahl, R. L. Articles by Zasadny, K. R.

Inhibition of Autoradiolysis of Radiolabeled Monoclonal Antibodies by Cryopreservation

University of Michigan Medical Center, Department of Internal Medicine, Division of Nuclear Medicine, Ann Arbor, Michigan

Correspondence: For reprints contact: Richard L. Wahl, MD, University of Michigan Medical Center, Div. of Nuclear Medicine, 1500 East Medical Center Dr., Ann Arbor, MI 48109-0028.

ABSTRACT

Autoradiolysis of therapeutic doses of monoclonal antibodies can occur rapidly, limits their shelf life and makes on-site radiolabeling a near-necessity. We evaluated freezing of three different ¹³¹I-labeled murine monoclonal antibodies at –70°C, immediately following radiolabeling, as a method of diminishing autoradiolysis, and of preserving immunoreactivity. Freezing greatly limits the ability of radiation-induced free radicals to diffuse in solution and thus produce radiolytic damage. By freezing at –70°C autoradiolytic damage of immunoreactivity of three different ¹³¹I monoclonal antibodies could be largely eliminated, in contrast to the 80–90% losses in immunoreactivity seen with storage at 4°C for a period of 1 to 12 days. Reduced in vitro deiodination rates are also seen for frozen antibodies. Limited studies with ¹²⁵I-labeled antibodies indicate autoradiolysis does occur, though at a slower rate per mCi than for ¹³¹I, and that this process is also retarded by freezing. Freezing may be valuable while quality control procedures are performed following radiolabeling as well as if temporary storage or shipment of radioantibodies prior to patient dosing is undertaken. While the approach should be validated for each antibody studied, freezing of therapeutic doses of monoclonal antibodies appears to be a simple and effective approach to the problem of autoradiolysis.

This article has been cited by other articles:

				G. W. Visser, R. P. Klok, J. W. K. Gebbinck, T. ter Linden, G. A. van Dongen, and C. F. Molthoff Optimal Quality 131I-Monoclonal Antibodies on High-Dose Labeling in a Large Reaction Volume and Temporarily Coating the Antibody with IODO-GEN J. Nucl. Med., March 1, 2001; 42(3): 509 - 519. [Abstract] [Full Text]

				M. S. Kaminski, J. Estes, K. R. Zasadny, I. R. Francis, C. W. Ross, M. Tuck, D. Regan, S. Fisher, J. Gutierrez, S. Kroll, et al. Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Blood, August 15, 2000; 96(4): 1259 - 1266. [Abstract] [Full Text] [PDF]

				M. S. Kaminski, K. R. Zasadny, I. R. Francis, A. W. Milik, C. W. Ross, S. D. Moon, S. M. Crawford, J. M. Burgess, N. A. Petry, G. M. Butchko, et al. Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody N. Engl. J. Med., August 12, 1993; 329(7): 459 - 465. [Abstract] [Full Text]